top of page
< Back

Dapagliflozin

達格列淨

Mechanism of action:

Dapagliflozin 是一種鈉-葡萄糖共轉運蛋白 2 抑制劑（SGLT2 inhibitor）。正常情況下，腎臟的近曲小管會透過 SGLT2 重新吸收約 90% 的濾過葡萄糖，其餘 10% 由 SGLT1 吸收。Dapagliflozin 能抑制 SGLT2 的功能，使葡萄糖無法再被吸收，隨尿液排出，導致血糖濃度下降；同時伴隨滲透性利尿與排鈉效應，可降低血壓並減少體液容積。

​Reference(s):

1. Obermeier M et al. (2010). In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 


2. Kasichayanula S et al. (2014). Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet.

bottom of page